Compare TRTX & VOGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRTX | VOGX |
|---|---|---|
| Founded | 2014 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 471.4M | 482.8M |
| IPO Year | 2015 | 2026 |
| Metric | TRTX | VOGX |
|---|---|---|
| Price | $6.24 | $18.87 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $9.54 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 73.7K |
| Earning Date | 10-26-2026 | 11-19-2026 |
| Dividend Yield | ★ 16.41% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.31 | N/A |
| P/E Ratio | $30.71 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.57 | $13.50 |
| 52 Week High | $9.37 | $38.41 |
| Indicator | TRTX | VOGX |
|---|---|---|
| Relative Strength Index (RSI) | 46.61 | 47.55 |
| Support Level | $5.57 | $14.41 |
| Resistance Level | $8.74 | $19.17 |
| Average True Range (ATR) | 0.21 | 2.53 |
| MACD | 0.07 | 0.46 |
| Stochastic Oscillator | 87.59 | 57.70 |
TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating-rate first mortgage loans that are secured by high-quality commercial real estate properties undergoing some form of transition and value creation.
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.